ENCORE: Exercise and Nutritional Interventions for Cardiovascular Health
Launched by DUKE UNIVERSITY · Dec 10, 2007
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
The present application seeks to extend previous findings by a) evaluating the efficacy of the DASH diet in a free-living situation; (b) considering the DASH diet alone and in combination with a behavioral weight loss program including aerobic exercise; (c) examining the impact of diet and exercise on cardiac, metabolic, and vascular function, including measures of arterial stiffness, endothelial function, baroreflex control, body composition, insulin resistance, cardiac hemodynamics, and left ventricular (LV) geometry and mass; and (d) following patients for one year to determine the longe...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Baseline SBP 130-159 mmHg (+/- 2mmHg) or DBP 85-99 mmHg (+/- 2 mm Hg)
- • 2. Age 35 years or older
- • 3. BMI 25.0-39.99 kg/m², with a maximum weight of 300 lbs
- • 4. Willing and able to participate fully in all aspects of the intervention
- • 5. Must currently be sedentary (less than 3x/wk for 30 mins each time)
- • 6. Informed consent
- Exclusion Criteria:
- • 1. Use of weight-loss medication and/or participation in a structured weight- loss program in the 3 months prior to 1st screening visit.
- • 2. Regular use of an anti-hypertensive drug or other drugs that raise or lower BP and if discontinued use, must be off for 1 month before screening
- • 3. Current use of insulin or oral hypoglycemic agents
- • 4. Current use of medications for treatment of psychosis or manic-depressive illness.
- • 5. ADHD medications (Ritalin/Aderol/amphetamines
- • 6. Cardiovascular Event
- • 7. Coronary Artery Disease
- • 8. Congestive Heart Failure
- • 9. Current symptoms of Angina for peripheral vascular disease
- • 10. Cancer diagnosis (except for non-melanoma skin cancer) or treatment in past 2 years
- • 11. Fasting blood sugar \>126 mg/dl
- • 12. Gastric Bypass/Bariatric Surgery
- • 13. Pyschiatric hospitalization in the past 2 years.
- • 14. Unable or willing to consume all of the dietary foods provided during the 2-week feeding.
- • 15. Consumption of more than 21 alcoholic drinks per week or binge drinking
- • 16. Alcoholism as determined by the Alcohol AUDIT (screening questionnaires)
- • 17. Planning to leave the area prior to the anticipated end of participation
- • 18. Body weight change of \>15lbs in the 3 months prior to the 1st screening visit
- • 19. Pregnant, breast feeding, or planning pregnancy prior to end of participation
- • 20. Current participation in another clinical trial until after completion of T2
- • 21. Investigator discretion for safety or adherence reasons
- • 22. Controlled substance abuse
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Patients applied
Trial Officials
James A. Blumenthal, Ph.D.
Principal Investigator
Duke University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials